Loading...

Haw Par Corporation Limited

H02.SI•SES
Healthcare
Drug Manufacturers - General
S$11.80
S$-0.07(-0.59%)

Haw Par Corporation Limited (H02.SI) Stock Overview

Explore Haw Par Corporation Limited’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
5.50%
↑ 5.50%
Profit Growth
S$1.06
↑ 5.40%
EPS Growth
S$1.06
↑ 5.20%
Operating Margin
28.20%
↓ 0.26%
ROE
5.98%
↑ 5.40%
Dividend Yield
0.00%
↑ 14.26%
Analyst Recommendations data is not available for H02.SIAnalyst Recommendations details for H02.SI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company operates through three segments: Healthcare, Investments, and Others. The Healthcare segment principally manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brand. Its Investments segment invests primarily in quoted securities. In addition, the company owns and leases various investment properties that have lettable area of 45,324 square meters of commercial and industrial space in Singapore and Malaysia. Further, the company provides family and tourist oriented leisure alternatives principally in the form of oceanariums. Haw Par Corporation Limited leases land, building, and office space, as well as offers management support services. The company was incorporated in 1969 and is based in Singapore.

CEO

Mr. Ee Lim Wee

Headquarters

No. 03-03 Haw Par Technocentre, Singapore

Founded

2000

Frequently Asked Questions